alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 9

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                          12,859
<INT-BEARING-DEPOSITS>                          10,833
<FED-FUNDS-SOLD>                                   300
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     46,815
<INVESTMENTS-CARRYING>                           6,358
<INVESTMENTS-MARKET>                                 0
<LOANS>                                        161,938
<ALLOWANCE>                                    (2,778)
<TOTAL-ASSETS>                                 254,053
<DEPOSITS>                                     219,368
<SHORT-TERM>                                    11,028
<LIABILITIES-OTHER>                              3,593
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         2,320
<OTHER-SE>                                      17,744
<TOTAL-LIABILITIES-AND-EQUITY>                 254,053
<INTEREST-LOAN>                                  7,409
<INTEREST-INVEST>                                1,619
<INTEREST-OTHER>                                   117
<INTEREST-TOTAL>                                 9,145
<INTEREST-DEPOSIT>                               3,238
<INTEREST-EXPENSE>                                 307
<INTEREST-INCOME-NET>                            5,600
<LOAN-LOSSES>                                      150
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  7,792
<INCOME-PRETAX>                                  2,004
<INCOME-PRE-EXTRAORDINARY>                       2,004
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,439
<EPS-BASIC>                                       0.65
<EPS-DILUTED>                                     0.65
<YIELD-ACTUAL>                                       0
<LOANS-NON>                                      1,824
<LOANS-PAST>                                       133
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                  1,572
<ALLOWANCE-OPEN>                                 1,612
<CHARGE-OFFS>                                      515
<RECOVERIES>                                       131
<ALLOWANCE-CLOSE>                                2,778
<ALLOWANCE-DOMESTIC>                             2,778
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
| 1.   | I have reviewed this Quarterly Report on Form 10-Q/A of Crimson Exploration Inc.; |
|----------------|-----------------------------------------------------------------------------------|

| 2.   | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  | August 30, 2010                       |   |
|-------------|---------------------------------------|--------|
|        | /s/ Allan D. Keel                     |   |
| Name:       | Allan D. Keel                         |   |
| Title:      | President and Chief Executive Officer |   |
|        |                                  |   |
|        |                                  |   |
1 Alberto Gonzales has been appointed to serve as Attorney General of the United States, and is substituted as responde nt pursuant to Federa l Rule of Appellate Procedure 43(c). 

## United States Court of Appeals FOR THE EIGHTH CIRCUIT

___________ No. 04-2036

___________ Roselor Jovial, * * Petitioner, * * v. * Petition for Review * of an Order of the Alberto Gonzales, 1 Attorney General * Board of Immigration Appeals. of the United States, * * [UNPUBLISHED] Respondent. *

___________ Submitted: September 26, 2006 Filed: October 5, 2006

___________ Before RILEY, COLLOTON, and GRUENDER, Circuit Judges.

___________ PER CURIAM. Roselor Jovial (Jovial) petitions for re view of an order of the Board of Immigration Appeals (BIA), which affirm ed without opinion an Immigration Judge’s (IJ’s) denial of asylum, withholding of removal, and relief under the Convention2 Jovial presents no argument on appeal rega rding the denial of CAT relief; thus, we need not considerthat claim. See Alyas v. Gonzales , 419 F.3d 756, 760 (8th Cir. 2005). -2- Against Torture (CAT). 2Jovial argues she suffered past persecution based on political opinion, as evidenced by her membership in the “Party Nationale for Democrat,” and by Ronald Kadav (Kadav) breaking into her apartment. Kadav is allegedly a known criminal who was a member of the Famni Lavalas party, the party of then-President Jean-Bertrand Aristide. Jovial also di sputes the IJ’s adverse credibility finding regarding the home invasion. We review the denial of asylum under the substantial evidence standard and will uphold the BIA’s findings “unless the evidence ‘[is] so compelling that no reasonable factfinder could fail to find the requisite fear of persecution.’” SeeVonhm v. Gonzales , 454 F.3d 825, 828 (8th Cir. 2006) (quoting INS v. Elias-Zacarias , 502 U.S. 478, 483-84 (1992)). This standard app lies to the IJ’s findings where the BIA issues a summary affirmance. See Dominguez v. Ashcroft , 336 F.3d 678, 680 (8th Cir. 2003) (summary affirmance by BIA adopts decision of IJ). We conclude the IJ’s finding that J ovial did not show she suffered past persecution or had a well-founded fear of future persecution on account of a protected ground is supported by substantial evidence. See Ngure v. Ashcroft , 367 F.3d 975, 990 (8th Cir. 2004) (noting isolated violen ce does not compel finding of persecution); Hamzehi v. INS , 64 F.3d 1240, 1242 (8th Cir. 1995) (w ell-founded fear must be both subjectively genuine and objectively reasonabl e). Jovial’s request for withholding of removal also fails. See Regalado-Garcia v. INS , 305 F.3d 784, 788 (8th Cir. 2002) (withholding of removal standard is mo re rigorous than asylum standard). Accordingly, we deny the petition. See 8th Cir. R. 47B.

______________________________
* Pursuant to Local Rule 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in Local Rule 47.5.4.

UNITED STATES COURT OF APPEALS

For the Fifth Circuit

No. 96-60171

(Summary Calendar)

EMPIRE FIRE AND MARINE INSURANCE COMPANY, 

Plaintiffs-Appellees.

v.

JERRY POWERS d/b/a POWERS USED CARS, INC., 

Defendants.

and

LOLA CAGLE, ROBERT CAGLE, and EMILY CAGLE,

Defendants-Appellants,

Appeal from the United States District Court

For the Northern District of Missippi

(1:94-CV228-JAD)

October 25, 1996

Before GARWOOD, JOLLY, and DENNIS, Circuit Judges.

PER CURIAM:*

Lola Cagle, Robert Cagle, and Emily Cagle, defendantsappellants, argue that the magistrate judge erroneously applied
Section 2-401(2) of the Uniform Commercial code in determining

ownership of the 1989 Buick Park Avenue vehicle at the time of the

accident instead of applying Section 63-21-31 of the Missippi Motor

Vehicle Title Act.

We have reviewed the parties’ briefs and the record and find

no reversible error. Accordingly, we AFFIRM for reasons assigned

by Magistrate Judge Davis.
###### Editorial Note on Part 330

#### Editorial Note:

Nomenclature changes to part 330 appear at 69 FR 13717, Mar. 24, 2004.

#### § 330.2 Pregnancy-nursing warning.

A pregnancy-nursing warning for OTC drugs is set forth under § 201.63 of this chapter.

[47 FR 54758, Dec. 3, 1982]
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               JUN-30-1996
<CASH>                                      10,529,069
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                             7,697,468
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                  8,946,481
<INVESTMENTS-CARRYING>                      39,202,063
<INVESTMENTS-MARKET>                         8,845,523
<LOANS>                                    115,611,657
<ALLOWANCE>                                  1,132,722
<TOTAL-ASSETS>                             187,091,528
<DEPOSITS>                                 166,982,499
<SHORT-TERM>                                 1,053,158
<LIABILITIES-OTHER>                            880,285
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     5,024,433
<OTHER-SE>                                  13,151,153
<TOTAL-LIABILITIES-AND-EQUITY>             187,091,528
<INTEREST-LOAN>                              5,704,465
<INTEREST-INVEST>                            1,405,964
<INTEREST-OTHER>                               274,105
<INTEREST-TOTAL>                             7,384,264
<INTEREST-DEPOSIT>                           2,790,106
<INTEREST-EXPENSE>                           2,827,304
<INTEREST-INCOME-NET>                        4,556,960
<LOAN-LOSSES>                                   75,000
<SECURITIES-GAINS>                               3,416
<EXPENSE-OTHER>                              3,498,300
<INCOME-PRETAX>                              1,840,628
<INCOME-PRE-EXTRAORDINARY>                   1,840,628
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,222,057
<EPS-PRIMARY>                                      .55
<EPS-DILUTED>                                      .53
<YIELD-ACTUAL>                                       0
<LOANS-NON>                                          0
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                     0
<CHARGE-OFFS>                                        0
<RECOVERIES>                                         0
<ALLOWANCE-CLOSE>                                    0
<ALLOWANCE-DOMESTIC>                                 0
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               DEC-01-1996
<CASH>                                       1,702,796
<INT-BEARING-DEPOSITS>                       5,480,521
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                 46,334,415
<INVESTMENTS-CARRYING>                         584,849
<INVESTMENTS-MARKET>                           585,885
<LOANS>                                     51,805,218
<ALLOWANCE>                                    436,171
<TOTAL-ASSETS>                             109,728,801
<DEPOSITS>                                  83,750,133
<SHORT-TERM>                                12,292,872
<LIABILITIES-OTHER>                          1,218,755
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         7,006
<OTHER-SE>                                  12,460,035
<TOTAL-LIABILITIES-AND-EQUITY>             109,728,801
<INTEREST-LOAN>                              1,161,966
<INTEREST-INVEST>                              774,535
<INTEREST-OTHER>                                18,191
<INTEREST-TOTAL>                             1,954,692
<INTEREST-DEPOSIT>                             936,429
<INTEREST-EXPENSE>                           1,091,217
<INTEREST-INCOME-NET>                          863,475
<LOAN-LOSSES>                                        0
<SECURITIES-GAINS>                              16,323
<EXPENSE-OTHER>                                685,896
<INCOME-PRETAX>                                324,261
<INCOME-PRE-EXTRAORDINARY>                     324,261
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   191,401
<EPS-PRIMARY>                                     0.32
<EPS-DILUTED>                                     0.31
<YIELD-ACTUAL>                                    0.85
<LOANS-NON>                                     43,700
<LOANS-PAST>                                   150,493
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               453,460
<CHARGE-OFFS>                                   18,778
<RECOVERIES>                                     1,489
<ALLOWANCE-CLOSE>                              436,171
<ALLOWANCE-DOMESTIC>                           379,620
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                         56,551
        

</TABLE>
<PAGE>   1
                                                                    EXHIBIT 99.1


PRELIMINARY PROXY

                         INTERLINQ SOFTWARE CORPORATION

             THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR
             THE SPECIAL MEETING OF SHAREHOLDERS ON APRIL __, 1999

The undersigned hereby appoint(s) Jiri M. Nechleba and Stephen A. Yount and 
each of them as proxies, with full power of substitution, to represent and vote 
as designated all shares of Common Stock of INTERLINQ Software Corporation (the 
"Company") held of record by the undersigned on February __, 1999 at the 
Special Meeting of Shareholders of the Company to be held at the Company's 
principal offices at 11980 N.E. 24th Street, Bellevue, Washington, at __ a.m. 
Pacific Standard Time on April __, 1999, or any adjournment or postponement 
thereof, with authority to vote upon the matters listed on the other side of 
this proxy card and with discretionary authority as to any other matters that 
may properly come before the meeting.

               IMPORTANT - PLEASE DATE AND SIGN ON THE OTHER SIDE



--------------------------------------------------------------------------------
                              FOLD AND DETACH HERE
<PAGE>   2
                                                            Please mark
                                                            your votes as
                                                            indicated on  [X]
                                                            this example


     THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" EACH OF THE PROPOSALS.

(1) PROPOSAL TO APPROVE THE AGREEMENT        FOR  AGAINST   ABSTAIN
    AND PLAN OF MERGER DATED DECEMBER 29,    [ ]    [ ]       [ ]
    1998 BETWEEN THE COMPANY AND TERLIN,
    INC. AND THE MERGER.

(2) PROPOSAL TO APPROVE THE REVERSE STOCK    FOR  AGAINST   ABSTAIN
    SPLIT AS CONTEMPLATED BY THE AGREEMENT   [ ]    [ ]       [ ]
    AND PLAN OF MERGER DATED DECEMBER 29,
    1998 BETWEEN THE COMPANY AND TERLIN, INC.



                                        SHARES REPRESENTED BY THIS PROXY WILL BE
                                        VOTED AS DIRECTED BY THE SHAREHOLDER IN
                                        THE SPACE PROVIDED. IF NO DIRECTION IS
                                        GIVEN, THIS PROXY WILL BE VOTED "FOR"
                                        EACH OF THE PROPOSALS.


Signatures(s): ___________________________________________ Date: _______________

Please sign your name exactly as it appears hereon. Attorneys, trustees, 
executors and other fiduciaries acting in a representative capacity should sign 
their names and give their titles. An authorized person should sign on behalf 
of corporations, partnerships, associations, etc., and give his or her title. 
If your shares are held by two or more persons, each person must sign. Receipt 
of the notice of meeting and proxy statements is hereby acknowledged.
--------------------------------------------------------------------------------
                             *FOLD AND DETACH HERE*
#### § 26.0 General.

This part substantially reflects relevant provisions of the framework agreement and its sectoral annexes on pharmaceutical good manufacturing practices (GMP's) and medical devices of the “Agreement on Mutual Recognition Between the United States of America and the European Community” (the MRA), signed at London May 18, 1998. For codification purposes, certain provisions of the MRA have been modified for use in this part. This modification is done for purposes of clarity only and shall not affect the text of the MRA concluded between the United States and the European Community (EC), or the rights and obligations of the United States or the EC under that agreement. Whereas the parties to the MRA are the United States and EC, this part is relevant only to the Food and Drug Administration's (FDA's) implementation of the MRA, including the sectoral annexes reflected in subparts A and B of this part. This part does not govern implementation of the MRA by the EC, which will implement the MRA in accordance with its internal procedures, nor does this part address implementation of the MRA by other concerned U.S. Federal agencies. For purposes of this part, the terms “party” or “parties,” where relevant to FDA's implementation of the MRA, should be considered as referring to FDA only. If the parties to the MRA subsequently amend or terminate the MRA, FDA will modify this part accordingly, using appropriate administrative procedures.
# C_2014135EN.01002701.xml

| 5.5.2014 | EN | Official Journal of the European Union | C 135/27 |
| --- | --- | --- | --- |

5.5.2014

EN

Official Journal of the European Union

C 135/27

---

Action brought on 10 March 2014 — European Commission v Portuguese Republic

(Case C-116/14)

2014/C 135/32

Language of the case: Portuguese

Parties

Parties

Applicant: European Commission (represented by: N. Yerrell and P. Guerra e Andrade, acting as Agents)

Applicant:

Defendant: Portuguese Republic

Defendant:

Form of order sought

Form of order sought

The European Commission claims that the Court of Justice shall:

| — | declare that, by failing to adopt and communicate the necessary guidelines, the Portuguese Republic has not complied with Article 8(1) and (2) of Directive 2008/96/EC (1) of the European Parliament and of the Council of 19 November 2008 on road infrastructure safety management; |
| --- | --- |

—

declare that, by failing to adopt and communicate the necessary guidelines, the Portuguese Republic has not complied with Article 8(1) and (2) of Directive 2008/96/EC (1) of the European Parliament and of the Council of 19 November 2008 on road infrastructure safety management;

1

| — | order the Portuguese Republic to pay the costs. |
| --- | --- |

—

order the Portuguese Republic to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Under Article 8(1) of Directive 2008/96/EC, Member States must ensure that guidelines, if they do not already exist, are adopted by 19 December 2011, in order to support the competent entities in the application of the directive.

More than two years after the expiry of the deadline for adopting those guidelines, Portugal has still not adopted them.

Under Article 8(2) of Directive 2008/96/EC, Member States must communicate those guidelines to the Commission within three months of their adoption.

As Portugal has not adopted any guidelines, it has failed to comply with the obligation to communicate.

---

(1)  OJ 2008 L 319, p. 59

1

---
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, November 22, 2019. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, November 22, 2019 The Court of Appeals hereby passes the following order A20A0263. LATASHA YVONNE WHITFIELD v. THE STATE.
Upon consideration of the APPELLANT'S motion FOR PERMISSION TO WITHDRAW THE APPEAL in the above styled case, it is ordered that the motion is hereby GRANTED.
#### § 573.820 Polyoxyethylene glycol (400) mono- and dioleates.

The food additive polyoxyethylene glycol (400) mono- and dioleates may be safely used as an emulsifier in calf-milk replacer formulations.